Kin Meds review

Kin Meds publishes entry prices for sermorelin injection, NAD⁺ in three routes, glutathione and GHK-Cu cream. That helps comparison, but some active options still lack a price: sermorelin troches and active testosterone products have intake links without public totals. Its privacy notice names Kin Meds/Manifest Pharmacy as program administrator; the product-specific dispensing pharmacy remains unidentified.

Kin Meds is a telehealth platform for weight, wellness, skin and hormone care. Current active pages include sermorelin injection and troches; NAD⁺ injection, nasal spray and troches; glutathione injection; GHK-Cu cream; and injectable TRT and enclomiphene intake links. Glutathione nasal spray and methylene blue remain marked as forthcoming. The platform describes independent prescribing networks and third-party pharmacy fulfillment. Its terms do not identify a Kin Meds incorporated operator or the dispenser for each order.

Online intake leads to review by an independent licensed provider. Published wellness entry prices include the provider visit, supplies and shipping; product pages offer 30- or 90-day supply selections without automatic subscription. A selected 90-day debit and dose-specific totals were not confirmed. TRT requires recent labs and a video visit. Sermorelin and all three NAD⁺ routes show California unavailability; there is no complete product-by-state list. The privacy notice names Kin Meds/Manifest Pharmacy as program administrator, which does not prove Manifest dispenses the selected prescription. Returns policy treats dispensed medication as final after charge and carrier handoff.

Sermorelin injection starts at $349 for 30 days; NAD⁺ injection starts at $249, nasal spray at $349 and active troches at $349. Glutathione injection starts at $249 and GHK-Cu face cream at $199. Active sermorelin troches and TRT/enclomiphene intakes do not show a public product total. Product pages offer 30- or 90-day selections, but a selected 90-day charge was not established. The $149/month branded GLP-1 consultation fee is separate from manufacturer-dispensed drug costs and is not a peptide price. Ask for the selected dose, first debit, any TRT lab charge and dispensing pharmacy.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Kin Meds states plainly that compounded medications have not been evaluated or approved by the FDA for safety, efficacy or quality. It is not itself a pharmacy, and its footer says only that compounded medications are prepared in a licensed 503A compounding pharmacy, without naming it. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the wellness menu is not one thing. Sermorelin is a GHRH analog that stimulates your own pituitary, a real and well-described mechanism whose long-term human outcome data remains thin; the troche form has less pharmacokinetic support than the injection. Injected, intranasal and sublingual NAD⁺ have no controlled human outcome trials — the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly — while oral NR and NMN reliably raise blood NAD⁺, a raised biomarker rather than a demonstrated benefit. Glutathione and GHK-Cu have essentially no controlled human outcome data. PT-141 (bremelanotide) is the outlier in the other direction: the injectable is an FDA-approved drug for one narrow indication, generalized hypoactive sexual desire disorder in premenopausal women, and a compounded version prescribed to anyone else is off-label use of an approved molecule. Individual results vary.